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Abstract
Telomeres, the nucleoprotein structures that cap the ends of eukaryotic chromosomes, play important and
multiple roles in tumorigenesis. Functional telomeres need the establishment of a protective chromatin
structure based on the interplay between the specific complex named shelterin and a tight nucleosomal
organization. Telomere shortening in duplicating somatic cells leads eventually to the destabilization of the
telomere capping structure and to the activation of a DNA damage response (DDR) signaling. The final
outcome of this process is cell replicative senescence, which constitute a protective barrier against unlimited
proliferation. Cells that can bypass senescence checkpoint continue to divide until a second replicative
checkpoint, crisis, characterized by chromosome fusions and rearrangements leading to massive cell death by
apoptosis. During crisis telomere dysfunctions can either inhibit cell replication or favor tumorigenesis by the
accumulation of chromosomal rearrangements and neoplastic mutations. The acquirement of a telomere
maintenance mechanism allows fixing the aberrant phenotype, and gives the neoplastic cell unlimited
replicative potential, one of the main hallmarks of cancer.
Despite the crucial role that telomeres play in cancer development, little is known about the epigenetic
alterations of telomeric chromatin that affect telomere protection and are associated with tumorigenesis. Here
we discuss the current knowledge on the role of telomeric chromatin in neoplastic transformation, with a
particular focus on H3.3 mutations in alternative lengthening of telomeres (ALT) cancers and sirtuin
deacetylases dysfunctions.
Keywords: Telomere, Cancer, Chromatin, Epigenetics, Sirtuins, Heterochromatin, ALT
Background
The presence of a mechanism to maintain telomeres - the
nucleoprotein structures at the end of human chromo-
somes - is essential to allow the indefinite proliferation cap-
acity of cancer cells. Due to the inability of DNA
polymerases to completely replicate the ends of linear DNA
molecules, known as the end-replication problem,
eukaryotic chromosomes shorten at each duplication cycle.
At birth, human telomeres typically consist of 10–15 kilo-
bases (kb) of double-stranded TTAGGG repeats ending in
a 50–400 nt long 3′-extension of the G-rich strand. Linear
ends need also to be protected from being recognized as
DNA breaks and being incorrectly repaired by fusion with
other chromosomes. End-protection is assured by a
six-protein complex, shelterin, which binds and cap telo-
meres (see ref. [1] for an extensive and complete review).
Human shelterin is anchored to double-stranded telomeric
DNA by the binding of TRF1 and TRF2; TIN2 connects
TRF1, TRF2, and TPP1, which in turn binds POT1, which
recognizes the single-stranded protrusion. The sixth pro-
tein, Rap1, interacts with TRF2. Shelterin caps human telo-
meres by forming t-loops, lariat-like structures in which the
single-stranded 3′-overhang invades the upstream
double-stranded telomeric DNA [2].
Telomere length maintenance and telomere protection
are interdependent, since telomere shortening induces telo-
mere deprotection and chromosome instability (see Fig. 1
for a schematic description). In most eukaryotes,
end-erosion is counteracted by the action of the ribonu-
cleoproteic enzyme telomerase, which adds short repeats to
the 3′ ends of chromosomes, the telomeres [3]. In humans,
telomerase is active only in germinal and in stem cells.
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Consequently, most human somatic cells undergo pro-
grammed telomere shortening [4]. When telomere attrition
is such to determine a loss of telomere protection, the acti-
vation of DDR at chromosome ends causes the arrest of cell
proliferation by inducing senescence or apoptosis (Mortal-
ity stage 1, M1) [5]. This telomere proliferation barrier has
long been recognized as a tumor suppressor mechanism
[6]. However, if mounting telomere dysfunction is coupled
to the impairment of pathways necessary for cell cycle
arrest, a transient event of telomere crisis (Mortality stage
2, M2) occurs, leading to extensive genome instability [7].
At this stage, dysfunctional telomeres do not anymore dir-
ect cells towards senescence but instead represent a source
of genomic instability that favors tumorigenesis [8, 9]. To
escape from crisis, incipient cancer cells require the
re-activation of telomerase or the establishment of a
telomerase-independent maintenance mechanism named
ALT, based on homologous recombination (HR) among
Fig. 1 Schematic representation of different healthy and pathological telomeric states. The figure shows the changes of the telomere structure
from a capped telomere to neoplastic transformations (from top to bottom). The t-loop structure, as several proteins that play a role at telomeres,
are not shown for sake of clarity. Capped telomere: the shelterin complex protect telomeres from DNA damage response and from DNA repair
pathways. Telomeric chromatin is maintained in a hypoacetylated, heterochromatic form by the action of the deacetylase SIRT6, ATRX promotes
the incorporation of histone H3.3 and resolves G-quadruplex structures and R-loops. Deprotected telomere: telomere shortening leads to the
disruption of the closed conformation and to the activation of DDR signaling. Cells undergo a growth arrest named replicative senescence or M1
(mortality stage 1). There is still enough shelterin proteins to block non-homologous end joining (NHEJ) and homologous recombination (HR)
pathways. Uncapped state: Inactivation of growth arrest checkpoint (p53) allows cells to bypass M1. This leads to excessive telomere shortening,
until cells reach a state termed crisis (or M2) characterized by extensive cell death. Telomeres are fully uncapped, loss of shelterin leads to
activation of DNA repair pathways, resulting in telomeric fusions. Rarely, premalignant cells escape from crisis acquiring a telomere maintenance
mechanism that permits unlimited proliferation. In most cases, by reactivating telomerase (on the left); 10–15% tumors develop an alternative
mechanism named ALT (on the right), characterized by high TERRA levels, R-loops, DDR, and maintenance of telomere length by
homologous recombination
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telomeres [10]. Telomere maintenance confers unlimited
proliferative potential to pre-neoplastic cells, allowing
also the stabilization of a heavily rearranged genome
that has acquired new and potentially tumorigenic
genetic mutations. In most cancers immortalization
derives from telomerase reactivation [11]; the
remaining 10–15% of tumors are telomerase-negative
and utilize the ALT mechanism of telomere mainten-
ance [12, 13]. Reactivation of telomere maintenance
programs also enables the transmission of abnormal
chromosomal structures (i.e., amplifications, deletions,
translocations, inversions) that arise as a result of it-
erative chromosomal breakage-fusion bridge cycles
[7].
Given the crucial role telomeres play in cancer devel-
opment, studying the mechanisms of telomere protec-
tion and the changes in telomere structure during
tumorigenesis is essential to understand the biology of
cancer and develop effective therapeutic strategies. Here
we review the modifications of the structure and the epi-
genetic state of telomere chromatin that occur upon
cancer establishment, with a particular emphasis on the
role of H3.3 mutations in pediatric ALT tumors and on
telomere dysfunctions derived by altered expression of
sirtuin deacetylases.
Structure of human telomeric chromatin
Shelterin complexes bind telomeric DNA as independent
units [14], in a chromatin environment characterized by
an atypical nucleosomal organization (see ref. [15] for a
review on the argument). Telomeric nucleosomes in
human cells have a repeat length of 160 bp, about 40 bp
shorter than in the rest of chromatin [16]. Moreover, in
vitro studies showed that telomeric nucleosomes are less
stable than average nucleosomes [17] and can slide along
telomeric DNA [18]. The telomeric nucleosomal
organization seems to persist until the very end of the
chromosome [19], limiting and affecting shelterin access
to telomeric DNA. Furthermore, studies on mouse cell
lines show that shelterin removal has no effect on the
nucleosomal organization at telomeres [19, 20]. These
results suggest that shelterin and the other proteins in-
volved in telomere function have to interplay with a
stable nucleosomal scaffold and not with naked DNA.
Kinetic studies showed that nucleosomes have a very
low turnover [21], whereas the proteins that compose
the shelterin complex have a very rapid exchange at telo-
meres [22], mainly by 3D diffusive search of telomeric
sequences [14]. Telomerase also accesses telomeres in
S-phase with high frequency [23]. In vitro studies
showed that the presence of nucleosomes modulates
binding of TRF1 and TRF2 to telomeric double-stranded
repeats [24, 25], indicating that TRF1 has a much higher
affinity than TRF2 both to nucleosomal binding sites
and to linker DNA. Other studies suggest that TRF2 can
induce compaction of telomeric chromatin [26] and that
TRF2 overexpression can alter nucleosomal spacing in a
cancer cell line [27].
Whether nucleosomal organization plays a role in
human telomere protection is still an open matter.
Recently, it was proposed that access of DDR factors to
deprotected telomeres might depend on decompaction
of telomeric chromatin upon loss of TRF1 and TRF2
[28]. Contrary to these findings, other recent works sug-
gest that DDR response at telomeres as a consequence
of shelterin depletion does not significantly change telo-
mere compaction and accessibility [29, 30]. Mammalian
telomeric chromatin is generally considered heterochro-
matic [31–33], enriched in heterochromatic marks such
as trimethylation of Lys9 of histone H3 (H3K9me3) and
Lys20 of histone H4 (H4K20me3) (Fig. 1). However, this
concept is based mainly on data obtained on mouse telo-
meres [34]. The epigenetic state at human telomeres is
less typically heterochromatic [15]. ChIP and ChIP-seq
experiments show unexpected low levels of H3K9me3 at
telomeres in human fibroblasts [35], in human CD4C
T-cells [36], and in nine human cell lines of different
origin [37, 38]. Clear heterochromatic marks such as
H3K9me3 and DNA hypermethylation characterize
instead subtelomeric regions [36, 38]. However, other
direct and indirect evidences support the importance of
a heterochromatic state for healthy human telomeres.
Specifically, hypoacetylation of lysines 9 and 56 of his-
tone H3 – a typical heterochromatic pattern - is essen-
tial for a correct telomere capping [39, 40]. In addition,
the heterochromatin protein HP1-γ interacts with the
shelterin protein TIN2 and is required for telomere co-
hesion during S-phase [41]. Another peculiar feature of
telomeric chromatin is the enrichment for the H3 his-
tone variant H3.3 [42]. H3.3 is expressed throughout the
cell cycle by two genes, H3F3A and H3F3B, located on
chromosomes 1 and 17, respectively. Enrichment for
H3.3 was first found within actively transcribed genes,
via a replication-independent deposition mechanism cat-
alyzed by the histone chaperone Histone Regulator A
(HIRA) [42, 43]. More recent studies showed that his-
tone H3.3 is also incorporated in telomeres by a com-
plex comprising the α-thalassemia/mental retardation
syndrome X-linked protein (ATRX) in cooperation with
the histone chaperone death domain-associated protein
6 (DAXX) [42, 44, 45], also involved in H3.3 deposition
at imprinted genes and interstitial heterochromatic sites
[46]. The HIRA complex and the ATRX-DAXX complex
control replication-independent deposition of H3.3 at
distinct sites on the genome [42, 45]. These specific
deposition mechanisms indicate that H3.3 has multiple
and distinct functions. The role played by H3.3 in telo-
mere homeostasis is still unknown.
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However, heterochromatin formation does not impede
that telomeres are actively transcribed to generate long
non-coding UUAGGG-repeated RNAs named TERRA
(telomeric repeat–containing RNA) [47, 48]. Even if the
mechanisms of TERRA functions have to be fully eluci-
dated, it is now commonly recognized that TERRAs are
implicated in important telomere functions [49], includ-
ing telomere homeostasis [50], and telomere protection
[51, 52]. Importantly, several evidences show that
TERRA interacts with TRF1 and TRF2 and is involved
in heterochromatin formation [53]. Moreover, it has
been shown that TERRA interacts with heterochromatin
protein 1 (HP1) and with telomeric chromatin contain-
ing H3K9me3 [53–55]. Upon TRF2 depletion, TERRA
transcription is upregulated and TERRA interacts with
the histone methyltransferase SUV39H1, promoting
methylation of histone H3K9 [56].
Shelterin alterations and cancer
Several mutations and/or altered expression in shelterin
components at telomeres have been described in cancer,
but how these components are regulated during differ-
ent stages of cancer development is not well understood.
Patients with early-stage chronic lymphocytic leukemia
(CLL) have an increased frequency of dysfunctional telo-
meres and telomere-to-telomere fusions are observed in
advanced stages of the disease [57, 58]. In agreement
with a role of telomere-dysfunction in CLL, reduced
expression levels of TRF1, RAP1 and POT1 [59], as well
as TIN2 and TPP1 [58] have been detected. Further-
more, somatic mutations in POT1 account for 5% of
CLL cases [60]. Of note, in addition to leukemia, muta-
tions in POT1 or RAP1 have been found to be mainly
associated with familial melanoma [61, 62], familial gli-
oma [63], Li-Fraumeni-like syndrome [64], mantle cell
lymphoma [65] and parathyroid adenoma [66]. The
malignant-predisposing mutations in the POT1 gene,
which alter the ability of the shelterin protein to bind to
single-stranded telomeric DNA, lead to the fusion of sis-
ter telomeres and are associated to increased telomere
length, owing to the loss of POT1-mediated inhibition of
telomerase [67]. These findings provide novel insights
into how genomic instability induced by dysfunctional
telomeres contributes to tumorigenesis. On one side,
POT1 inhibition may result in defective telomere repli-
cation caused by impaired CST (CTC1-STN1-TEN1)
function at telomeres, thus promoting a telomere-driven
genome instability [68]. On the other, the presence of
longer telomeres may reduce the tumor-suppressive
effects of telomere attrition as consequence of a delayed
senescence onset in precancerous dividing cells.
Additionally, POT1 and RAP1 expression appeared
deregulated in hepatocellular carcinoma (HCC) [69].
Finally, TRF1 and TRF2 were reported to be
up-regulated in several cancer types such as lung,
gastric, breast, colon and renal tumors [70–74]. The role
of the shelterin gene mutations in cancer rely mainly on
the perturbation of their telomere-related activities
impacting on telomere integrity. However, the putative
roles of TRF2 in tumorigenesis, as well as of RAP1, have
been ascribed also to extra-telomeric functions. By
combining chromatin immunoprecipitation with
high-throughput DNA sequencing (ChIP-Seq), it has
been shown that TRF2 and RAP1 occupy both telomeric
and extratelomeric TTAGGG repeats throughout the
human genome, referred to as interstitial telomeric
sequences (ITSs), where they can affect gene transcrip-
tion [75–77]. Specifically, RAP1 associates to both subte-
lomeric related genes and genes linked to metabolic
regulation, cell adhesion, and cancer [75]. Additionally,
RAP1 can translocate to the cytoplasm, where it acts as
a modulator of the NF-kB signaling pathway by interact-
ing with IKK complex. The RAP1-IKK interaction is re-
quired for the phosphorylation of the p65 subunit of
NF-kB, enabling it to perform gene transcriptional acti-
vation [78]. By binding ITSs, TRF2 modulates the
HS3ST4 gene, encoding heparan sulfate (glucosamine)
3-O-sulphotransferase 4, which is involved in regulating
NK cell recruitment/activation at the tumor site with an
impact on tumor take/growth [79]. By localizing directly
to specific promoter regions, TRF2 regulates the expres-
sion of the platelet-derived growth factor receptor-β
(PDGFRβ; [80]), thus promoting angiogenesis; further-
more, TRF2 represses the cyclin-dependent kinase p21
(CDKN1A/CIP1/WAF1) through the REST-LSD1 re-
pressor complex recruitment [81].
Collectively, these findings implicate that an altered
expression of shelterin genes, besides impacting on telo-
mere homeostasis, may have substantial consequences
on extra-telomeric loci, thus integrating telomeric chro-
matin alterations with aberrant gene transcription pro-
files. Consistently, looping of telomeres to interstitial
sites, referred to as interstitial t-loops, mediated through
TRF2 and lamin associations has been reported [82].
More recently, Mukherjee et al. [83] have shown that
binding of TRF2 at promoters about 60 Mbp from
chromosome ends depends on telomere length in hu-
man cells. Promoter TRF2 occupancy was affected in
cells with elongated telomeres producing an altered
TRF2-mediated transcription of distal genes.
Epigenetic alterations of telomeric chromatin in
cancer
It is still not clear whether telomerase-positive cancer
cells are characterized by a specific epigenetic pattern.
Roles for epigenetic regulation of telomere maintenance
have been reported in mouse. Knockout of various chro-
matin remodeling factors (CRFs), such as histone
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methyltransferases SUV39H1/2, SUV4-20H1/2 result in
defective telomere function, aberrantly increased telo-
mere length, and chromosomal instability (see ref. [84]
for a review). In humans, SIRT1 and SIRT6, both mem-
bers of the mammalian sirtuin family of Nad +
−dependent histone deacetylases, are among the most
extensively studied CRFs interacting with
telomere-repeats implicated in telomere integrity [39,
85–90]. Specific epigenetic changes have been associated
with ALT cancers, such as the increase of TERRA tran-
scription and enrichment of heterochromatic marks
[52]. Importantly, high frequency of H3.3 point muta-
tions and/or ATRX/DAXX mutations have been
associated with pediatric cancers [91–94] and with the
establishment of a ALT mechanism of telomere main-
tenance [95].
Sirtuins
Deacetylation activity of SIRT1 is directed against both
histone and non-histone targets, implying the involve-
ment of SIRT1 in several cellular functions including
energy metabolism, cellular stress resistance, genomic
stability, aging and tumorigenesis (reviewed in [96]).
SIRT1 was firstly demonstrated to be recruited to telo-
meres in murine pluripotent stem cells (iPSCs) and to
positively regulate telomere length in both mouse
embryonic fibroblasts and tissues [86]. Chen et al. [88]
have reported that SIRT1-silencing causes nuclear
abnormalities, telomere dysfunction induced foci and in-
duced cellular senescence in HCC cells by inhibiting the
shelterin TPP1 expression. Indeed, up-regulated expres-
sion of TPP1 in SIRT1-depleted HCC cells improved
cellular senescence, strongly suggesting that TPP1 was
closely involved in the SIRT1-mediated anti-senescence
effects in HCC cells [88]. Another study showed that
SIRT1 is necessary for telomere elongation after repro-
gramming of murine and human somatic cells, and it is
required to maintain genomic stability, telomeric tran-
scription and remodeling of telomeric chromatin [90].
SIRT6 is a complex enzyme with multiple substrates
and catalytic activities, as deacetylation of both histones
and non-histone proteins, deacetylation of long-chain
fatty acyl groups and mono-ADP-ribosylation activity
[97]. At chromatin level, SIRT6 deacetylates the histone
H3 on acetylated K9, K56 [39, 98] and the more recently
identified K18 and K27 residues [98–100], causing the
repression of many genes differently involved in inflam-
mation, aging, genome stability, metabolic pathways and
telomere integrity [101, 102]. Upon DNA damage, SIRT6
is recruited to double strand breaks (DSBs) ensuring the
proper activation of downstream DDR factors leading to
an efficient repair [87]. In 2008, Michishita et al. [39]
showed that SIRT6-mediated deacetylation of histone
H3 on acetylated lysine 9 (H3K9ac) modulated telomeric
chromatin structure. Specifically, SIRT6 can localize to
the telomeric chromatin and its loss leads to the dys-
function of telomeres resembling a phenotype of telo-
mere abnormality similar to that of Werner syndrome
[39, 40, 98], with chromosome end fusions and cellular
senescence. The Werner syndrome ATP-dependent heli-
case (WRN) is a well-known RecQ-like helicase that
plays a major role in genome stability, particularly
during DNA replication and telomere metabolism [103].
In detail, SIRT6 deacetylates H3K9 at telomeric chroma-
tin and is required for the stable association of WRN.
Additionally, SIRT6 is required for proper replication of
telomeres by deacetylating H3K9 and H3K56 during
S-phase [40]. Thus, depletion of SIRT6 from human
cells resulted in abnormal telomere structures and sto-
chastic replication-associated telomere sequence loss, ul-
timately leading to chromosomal end-to-end fusions and
consequent genomic instability [87]. A very recent paper
attributes to SIRT6 the ability to facilitate directional
telomere movement upon oxidative damage by recruit-
ing SNF2H (an ATP-dependent chromatin-remodeling
factor) with resulting local chromatin decondensation at
telomeres [104]. Another important function of SIRT6 at
telomeres is the ability to prevent impaired telomere
position effect (TPE), the epigenetic silencing of
telomere-proximal genes [87]. Indeed, RNAi-mediated de-
pletion of SIRT6 abrogated silencing of both an integrated
telomeric transgene and an endogenous telomere-prox-
imal gene. Moreover, enhanced telomeric silencing in re-
sponse to telomere elongation is associated with increased
repressive chromatin marks, and this heterochromatic mi-
lieu is lost in SIRT6-deficient cells. These findings may be
relevant in suggesting an additional mechanism by which
telomeric chromatin may contribute to tumorigenesis.
Since aberrant expression of silent chromatin has been in-
creasingly recognized to have a role in cancer [105], it
would be interesting to understand if telomere erosion, as
well as SIRT6 inhibition —and consequent de-repression
of telomere-proximal genes—may impact on
cancer-related changes in gene expression [106, 107].
Interestingly, in line with this notion, recently pub-
lished data suggest that histone modifications typical
of chromatin compaction (H3K27me3) or access
(H3K4me1 and H3K4me3) to regulatory factors, at
sites distant from telomere ends depend on telomere
length [83]. Moreover, loss of silencing factors from
shortening and/or dysfunctional telomeres might lead
to a relocalization of these factors from chromosome
ends to other genomic loci, triggering aberrant silen-
cing of non-telomeric genes [108].
The role of SIRT6 in cancer is controversial. In some
tumors, high levels of SIRT6 are associated with poorer
outcomes [109, 110]. In other tumors, including colorec-
tal cancer (CRC), SIRT6 functions are associated with its
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tumor suppressive activity [111–113]. Of note, the telo-
meric protein TRF2 has been newly identified as a novel
substrate of SIRT6. Upon exposure to a DNA damaging
agent, SIRT6-dependent lysine deacetylation of TRF2
leads to the ubiquitin-dependent proteolysis of the shel-
terin protein, resulting in downstream proper activation
of DDR machinery [114]. An inverse correlation between
SIRT6 and TRF2 protein expression levels have been
also found in a cohort of CRC patients [114], suggesting
that an impairment of TRF2 degradation, as a conse-
quence of SIRT6 loss, could be one of the mechanisms
underlying the increased dosages of TRF2 observed in
many human malignancies. Whether SIRT6 could also
impact on the binding affinity to DNA of TRF2 (and
eventually of other shelterin factors) through histone
deacetylation remains to be fully elucidated.
ATRX/DAXX mutations in ALT tumors
Several immortalized cell lines and 10–15% of tumors
are telomerase-negative and maintain functional telo-
meres by utilizing an ALT mechanism (for a review, see
refs. [10, 115, 116]). ALT activity has been detected
prevalently in cancers from mesenchymal tissues such as
bone, soft tissues, neuroendocrine systems, peripheral
and central nervous systems [12, 117]. ALT cells show
several unusual features, such as highly heterogeneous
telomere length [118]. Other markers for ALT include
abundant extra-chromosomal double-stranded telomeric
DNA prevalently in circular form (t-circles), partially
single-stranded telomeric C-rich circles (C-circles), high
telomere-specific DDR, telomere sister chromatid
exchanges (tSCEs) and formation of APBs (ALT-asso-
ciated promyelocytic leukemia (PML) nuclear bodies),
containing chromosomal or extra-chromosomal telo-
meric DNA, telomere-associated proteins, and proteins
involved in homologous recombination (reviewed in
[10]). Several evidences indicate that ALT maintenance
is based on DNA recombination [10, 115]. For example,
a DNA tag inserted in a single telomere was copied to
different telomeres in human ALT cells, but not in
telomerase-positive cells [119]. Since HR at telomeres is
repressed in normal cells and in telomerase-positive
immortalized cells, ALT activation likely requires the in-
activation of factors repressing HR. The protein ATRX
(a chromatin remodeler of the SWI/SNF family) not only
does inhibit HR, but is also able to repress ALT activity
if transiently expressed in ALT-positive/ATRX-negative
cells [120]. ATRX also binds telomeric repeats and
G-quadruplex structures in vitro [121], suggesting that it
might play a role in resolving G-quadruplex structures
forming at telomeres during replication, thus inhibiting
replication fork stalling. Through its ADD domain,
ATRX interacts with H3K9me3 [122] and its localization
at telomeres is antagonized by TERRA [51]. TERRA also
plays a role in ALT that remains to be fully defined. In
ALT cancer cells, TERRA levels are higher than in
telomerase-positive cancer cells and TERRA transcripts
constitutively associate with telomeres [123]. Moreover,
a recent finding shows that TERRA directs the enrich-
ment of HP1, H3K9me3, H3K27me3, H4K20me3 in the
ALT cell line U2OS, through the recruitment of Poly-
comb repressive complex 2 (PRC2) [52], typical of facul-
tative heterochromatin. Importantly, at chromosome
ends TERRA molecules form RNA-DNA hybrids
(R-loops), three-stranded nucleic acid structures consist-
ing of a DNA:RNA hybrid and a displaced DNA strand.
The displaced G-rich DNA strand is thought to form
G-quadruplex structures, which may cause stalling of
replication and DNA damage at telomeres [124], thus in-
creasing homologous recombination among telomeres
[125]. Suppression of R-loop formation is one of the
multiple functions of ATRX [124], consistent with its
ALT suppressing role. However, the main role of ATRX
is the deposition - together with the histone chaperone
DAXX - of the histone variant H3.3 at pericentric
heterochromatic regions and at telomeres [42, 45]. At
the moment, it is unknown which role H3.3 deposition
at telomeres plays in the development of ALT pathway.
However, the importance of the ALT/DAXX/H3.3 path-
way is supported by recent surveys of ALT-positive
tumors showing a high frequency of mutations in
ATRX/DAXX and/or H3.3 [92–95].
H3.3 mutations in pediatric tumors
Recent studies reported high frequencies of H3.3 muta-
tions in pediatric cancers, often associated with ALT (for
a review see [91, 126]). Three residues are involved,
respectively Lys27, Gly34, and Lys36. Mutated
H3.3K27M (from Lysine to Methionine) and H3.3G34R/
V (from Glycine to Arginine or Valine) are frequent in
pediatric high-grade glioma (pHGG) or in diffuse intrin-
sic pontine gliomas (DIPG) [94, 127, 128]. Other two
mutations, H3.3K36M and H3.3G34W/L (from Glycine
to Tryptophan or Leucine), have been found at high fre-
quency in two juvenile bone tumors, chondroblastomas
and giant cell tumors of the bone (GCTBs) [129]. A rare
mutation, H3.3K27I (from Lysine to Isoleucine) has been
also described in DIPG [130]; moreover, K27M mutation
can affect also the canonical histones H3.1 and H3.2
[127, 128, 130]. Although both genes express the same
protein product, mutations occur either in H3F3A or in
H3F3B gene. Mutations regarding residues K27 and G34
affect preferentially H3F3A gene, whereas K36M muta-
tions occur mostly in H3F3B [91]. These missense muta-
tions act in heterozygosis, indicating a “gain of function”
role of the mutated histone in cancer development. Re-
markably, mutant histones - termed as “oncohistones”
[91] due to their dominant nature - are found in
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pediatric and juvenile tumors but rarely in their adult
counterparts. Another peculiar feature is that the ana-
tomical location, the average age at diagnosis, and the
overall survival are highly mutation-specific [127, 128,
131]. H3.3G34R/V cancers are found almost exclusively
in the cerebral hemispheres, accounting for 16.2% of
total cases, and show a longer overall survival compared
with other H3.3 mutant groups (median 18 months).
H3.1/H3.2 K27M are restricted to the pons (21.4%) and
show a median survival of 15 months. H3.3K27M muta-
tions are abundant in the midline and pons, accounting
for 63.0% DIPG and 59.7% non-brainstem midline tu-
mors. This group is characterized by a shorter overall
survival (median 11 months). The reason for these speci-
ficities and the molecular mechanisms at the basis of
oncohistones are mostly unknown. The amino acids that
are mutated in tumors are sites of possible methylation
or acetylation (K27 and K36), or can interfere with
post-translational modifications of close lysines (G34).
However, the most striking feature of oncohistones is
that they act globally, despite the fact that they are
expressed by a single allele. Pediatric glioblastomas har-
boring H3.3K27M mutation show a global reduction of
H3K27me3 [132–134]; to a lesser extent, also K27I
reduces the global levels of H3K27me3 [132]. Trimethy-
lation of H3K27 is a mark of facultative heterochroma-
tin, catalyzed by PRC2 [135, 136]. In vitro analysis of
PRC2 methyltransferase activity and crystal structure
studies show that H3K27M inhibits K27 methylation
through specific binding to EZH2, the enzymatic subunit
of PRC2 [132, 137], leading to a general reprogramming
of H3K27me3 and EZH2 on the genome [138]. Recent
data suggests that in vivo H3K27M does not bind or
sequester PRC2 but instead forms heterotypic
H3K27M-K27 ac nucleosomes that interact with bromo-
domain proteins [139]; in agreement with these results,
a recent study shows no increased Ezh2 affinity for
nucleosomes containing H3K27M [140].
Similarly to H3K27M mutations, H3.3K36M expres-
sion in chondroblastoma correlates with global reduc-
tion in H3K36 methylation [141], due to inhibition of
NSD2/MMSET, a methyltransferase that catalyzes
mono- and di-methylation of H3K36, and SETD2, which
catalyzes trimethylation of H3K36me2 [141, 142]. Analo-
gously to H3K36M, it has been proposed that
H3.3K36M might act by sequestering NSD2 and SETD2;
support to this hypothesis comes from the crystal struc-
ture showing a strong binding of H3K36M to the cata-
lytic site of SET2D [143, 144].
The last H3 residue mutated in a subset of pediatric
cancers, H3.3G34, is not a site for post-translational
modifications, but is in close proximity of H3K36.
Indeed, structural analysis showed that H3.3G34R/V/D
mutations result in a steric hindrance to the catalytic
activity of SETD2 on H3K36 [145]. As a consequence,
H3K36 methylation is inhibited also by mutations of
H3.3G34 [132, 146], but only in cis on the mutant nucleo-
somes, whereas nucleosomes containing wild-type H3 are
not affected by the mutations [132, 146]. Very recently, it
has been shown that targeted G34R mutations on one
allele of H3f3a in mouse embryonic stem (ES) cells
resulted in a global epigenetic change [147], namely the
inhibition of the KDM4 family of histone demethylases,
which target H3 residues K27 and K36. Further analyses
are necessary to assess the importance of KDM4 demethy-
lases inhibition in H3.3G34R/V tumors.
Therapeutic strategies
Therapeutic strategies targeting chromatin modifications
are defined as epigenetic therapy. Currently, epigenetic
therapy has been proven to be a successful approach for
the treatment of hematological malignancies, but little
success has been achieved in the treatment of solid
tumors (for a recent review see [148]). However, accu-
mulating data on the role of epigenetic alterations occur-
ring at telomeres of cancer cells provides an intriguing
and challenging chance for potential targeted therapeutic
interventions.
The essential dependence of cancer cells on a telo-
mere maintenance mechanism for replicative
immortalization led researchers to investigate these
mechanisms as potential cancer-specific therapeutic
targets. Given the majority of carcinomas and soft tis-
sue cancers present telomerase activity, whereas
telomerase is absent in most normal tissues [11, 149],
several efforts have been made to inhibit telomerase
by pursuing different strategies: small-molecule inhibi-
tors, antisense oligonucleotides, G-quadruplex stabi-
lizers, immunotherapy, telomerase-driven suicide gene
therapy, and chemicals blocking telomerase biogenesis
(see ref. [150] for an extensive review). Unfortunately,
anti-telomerase approaches have showed effectiveness
in only some myeloid tumors but have largely failed
in solid tumors (reviewed in [151]). The limitations of
targeting telomerase, and the fact that telomerase
inhibition would not affect cancer cells using the ALT
pathway, encouraged researchers to investigate alter-
native therapeutic approaches targeting telomeres in a
telomerase- and telomere length-independent manner.
In agreement with growing findings about the altered
telomeric chromatin composition of cancer cells, and
considering the pivotal role of shelterin components
in telomere protection, targeting telomeric binding
factors has been developing as an emerging antitumor
approach. Indeed, chemical inhibition of TRF2 [152]
or TRF1 [153, 154] were reported to induce rapid
DDR activation and growth arrest both in in vitro
and in vivo tumor models, respectively.
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Until now, telomeric chromatin alterations in cancer
have not yet been considered in the design of effect-
ive epigenetic therapy, however they can be indirectly
targeted by novel identified epigenetic drugs. Due to
the broad range of activities and substrates, Sirtuins
are involved in several cellular processes, including
telomere integrity, but their role in cancer is contro-
versial. These reasons led to the identification of
many sirtuin modulators over recent years, both in-
hibitors and activators, mainly through chemical li-
brary screening and catalytic mechanism-based design
approaches (reviewed in [155]). Very recently, new
chemical activators of SIRT6 have been identified. It
has been shown that UBCS039 and MDL-800 are able
to inhibit the proliferation of various cell lines regard-
less of tumor histotype [156–158]. Moreover,
MDL-800 compound showed efficacy in a xenograft
model of hepatocellular carcinoma [158]. Given the
described ability of SIRT6 to affect the protein stabil-
ity of TRF2 [114], as well as telomere capping, it is
reasonable to ask whether the antitumor activities
caused by the exposure to SIRT6 activators can be
partially attributable to telomere-driven effects. To
address this issue, further studies will be needed.
Importantly, there is mounting evidence showing that
epigenetic cancer therapy could target ALT-positive
gliomas harboring H3.3 mutations [159]. Specifically,
recent preclinical studies showed that GSKJ4, a small
molecule inhibitor of the histone H3K27 demethylases
JMJD3 (KDM6B) and UTX (KDM6A), decreased tumor
cell viability and increased H3K27me3 levels in glioma
cell lines harboring the mutation of lysine to methionine
substitution at codon 27 (K27M), and significantly
extended survival of mice with K27M mutant glioma xe-
nografts [160]. In contrast, GSKJ4 has not shown activity
in an H3.3G34V mutant glioma cell line [160]. Panobi-
nostat, a histone deacetylase inhibitor, resulted in de-
creased tumor cell viability in both K27M mutant
glioma cell lines and in mice with K27M mutant glioma
xenografts [161, 162]. Panobinostat treatment demon-
strated a dose dependent increase in histone acetylation
and in H3K27me3 [161, 162]. Combined use of GSKJ4
and panobinostat produced a synergistic reduction of
tumor cell viability in K27M mutant glioma cell lines
[161]. Other strategies to modulate histone methylation
are under study, such as targeting EZH2, the histone
demethylases KDM1 and KDM5 (see refs. [91, 126, 163]
for a review). Strategies that modulate DNA methylation
at subtelomeres in ALT are expected to affect cell sur-
vival of ALT cells. Additionally, inhibitors of the protein
kinase ATR, a regulator of homologous recombination
with prolonged recruitment to telomere ends in the set-
ting of ATRX mutation, have been found to selectively
induce death of ALT-positive cancer cells [123].
Conclusions
Telomeres and telomerase have become a main target in
developing anticancer strategies, due to their crucial role
in cancer development. Many efforts have been focused
on telomerase inhibition, however this strategy has
therapeutic limits. New anticancer targets could emerge
from a clearer comprehension of telomere structure and
dynamics. Several aspects of telomere biology need a
deeper investigation: the epigenetic pattern of human
telomeres is still controversial [38], the role played by
the histone H3.3 at telomeres is largely unknown, how
telomeric chromatin changes during neoplastic trans-
formation is an issue mostly unexplored.
Effective anticancer strategies require an accurate
mapping of the mutations causing the disease, with the
ultimate goal to precisely tailor the therapy to the
patient. Besides genetic mutations, it is now generally
recognized that epigenetic changes play an important
role in cancer development [164, 165]. Even if still
poorly defined, strategies directed against epigenetic tar-
gets have features that can potentially complement clas-
sical anticancer approaches, like the possibility to
address different pathways at the same time. Character-
izing the telomeric epigenome is therefore an important
issue, both for a deeper understanding of the telomere
protective structure and because it might lead to the
emergence of new anti-cancer targets.
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